By Jim Spencer and Joe Carlson Star Tribune   U.S. Sen. Al Franken says Medtronic’s handling of a study of its Infuse Bone Graft product may have “potentially skewed the risk profile” for thousands of patients and exposed “insufficient vigilance” by the Food and Drug Administration. Franken raised both concerns in letters delivered Tuesday to […]